# Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

> **NCT00282100** · PHASE2 · UNKNOWN · sponsor: **Tan Tock Seng Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** Gefetinib (Iressa)

## Key facts

- **NCT ID:** NCT00282100
- **Lead sponsor:** Tan Tock Seng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-12
- **Primary completion:** 2019-09
- **Final completion:** 2019-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-04-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00282100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00282100, "Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00282100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*